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Abstract
Tumor cells and tumor-associated endothelial cells
express activated epidermal growth factor receptor
(EGFR) due to production of EGF-related ligands in
the tumor microenvironment. To investigate the effect
of perpetual EGFR activation on endothelial cells, we
developed a novel method to generate constitutively
active EGFR.We fused the entire intracellular domain of
the EGFR to the N-terminus of the CD3Z component of
the T-cell receptor signaling complex. Expressionof the
chimeric receptor CD3-EGFR in EGFR-deficient human
embryonic kidney cells resulted in ligand-independent
sustained EGFR phosphorylation and in the induction
of Akt, mitogen-activated protein kinase, and signal
transducer and activator of transcription 3 (Stat3). Next,
CD3-EGFR, was stably expressed in murine brain en-
dothelial cells where it signaled for the initiation of
angiogenic programs, Stat3 activation, and continuous
proliferation. A comparison between brain endothelial
cells encoding CD3Z and CD3-EGFR revealed that pro-
angiogenic phenotype was modulated by the intra-
cellular effector Stat3 and that suppression of this
downstream target with the EGFR tyrosine kinase in-
hibitor PKI166 could revert this phenotype. Thus, our
results validate the use of chimeric constitutively active
receptors to replicate critical features observed in
pathophysiological processes that can expedite the
identification of novel therapeutic agents targeting
EGFR activation and function.
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Introduction
Epidermal growth factor receptor (EGFR) is a member of
the erbB superfamily, which shares structurally related
receptor tyrosine kinases [1]. EGFR comprises a ligand-
binding extracellular domain, a transmembrane domain
containing a single hydrophobic anchor sequence, and a
cytoplasmic region containing the kinase domain and dis-
tinctive C-terminal tyrosine residues [2]. The receptor forms
homodimers and heterodimers as a result of ligand-induced
alterations in conformation and activation. On activation,
thedimerized receptor transphosphorylates itsC-terminal ty-
rosine residues, which leads to the recruitment of SH2 domain–
containing molecules to the plasma membrane. In turn, these
molecules activate several downstream effectors, including
mitogen-activated protein (MAP) kinase, phosphatidylinositol
3-kinase/Akt, and signal transducer and activator of transcrip-
tion (STAT) [3–5]. EGFR is activated in response to various
physiological and pathologic stimuli [6], and overexpression
or mutation of EGFR is a hallmark of a variety of tumors, in which
it transduces signals that promote cell proliferation, invasion,
angiogenesis, and, ultimately, metastasis [7,8]. Consequently,
much effort has been directed toward developing agents that
target EGFR activation and function.
An expanding body of evidence indicates that tumor cell
expression of transforming growth factor alpha (TGF-a), a pri-
mary ligand for EGFR, correlates with a more aggressive phe-
notype [9–11]. In addition to enhancing cell growth, TGF-amay
also provide a survival advantage for malignant cells by sig-
naling for the expression of antiapoptotic proteins (e.g., Bcl-xL
and nuclear factor kappa B) [12,13]. Recent evidence suggests
that tumor-secreted TGF-a may act in a paracrine manner to
convey information to blood vessels that perfuse malignant tis-
sues. Molecular profiles constructed on tumor endothelial cells
indicate that they differ from endothelial cells residing in normal
tissues [14], and that one distinguishing feature of tumor
endothelial cells is their tendency to express EGFR [15]. In fact,
examination of tumor vasculature in xenograft models [16] and
of spontaneously arising tumors in man [17] has suggested that
EGFR is activated in the tumor endothelium. The importance of
EGFR signaling on tumor blood vessels to malignant progres-
sion is exemplified by a growing number of preclinical reports
demonstrating that pharmacologic suppression of EGFR acti-
vation on tumor-associated endothelial cells significantly
impedes the growth of primary tumors and, more importantly,
reduces the frequency of metastasis [17–20]. Collectively,
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these data suggest that EGFR expression is restricted to
endothelial cells in pathologic tissues and that EGFR activa-
tion is critical to the growth and dissemination of tumors.
However, a detailed study of the molecular and cellular role
of EGFR signaling on tumor endothelial cells has been
problematic because no tumor endothelial cell lines are
available for study and because replicating the tumor micro-
environment in cell culture is not feasible.
Previously, we reported the establishment of a broad
panel of organ-specific endothelial cell lines with which to
study angiogenesis and metastasis [21]. Each of these cell
lines expresses a temperature-sensitive SV40 large T anti-
gen, thereby allowing regulation of the rate of cell division and
differentiation by adjusting environmental conditions. More
recently, we demonstrated that these lines can be used to
define the molecular basis of therapeutic intervention [22].
Because EGFR expression is characteristic of tumor endothe-
lium and because EGFR activation may enhance the growth
and spread of neoplasms, we wanted to generate an endo-
thelial cell line that constitutively expresses activated EGFR.
In addition to replicating a key component in tumor vascu-
lature, such a line would provide novel information on intra-
cellular signaling pathways that may lead to the identification
of new targets for anticancer therapy. Herein, we describe our
unique approach to generating cells that express constitu-
tively active EGFR and we report the consequences of
persistent EGFR activation in brain endothelial cells. Stable
introduction of the ligand-independent CD3-EGFR chimeric
receptor into brain endothelial cells initiated the activation of
programmed angiogenic responses and signals for continu-
ous proliferation, both of which were modulated by the intra-
cellular effector Stat3. The newly acquired phenotype of brain
endothelial cells was susceptible to the small-molecule tyro-
sine kinase inhibitor PKI166. These results validated our
tumor endothelial cell model. Our approach to constructing
a constitutively active chimeric receptor might be broadly ap-
plied to defining downstream effects of other diseases and
developing molecular targeted therapies.
Materials and Methods
Cell Cultures and Antibodies
Human embryonic kidney (HEK) cells (American Type
Culture Collection, Manassas, VA) and SB2 cells (human pri-
mary melanoma cells; generously provided by Dr. Menashe
Bar-Eli, M. D. Anderson Cancer Center, Houston, TX) were
grown in Dulbecco’s minimum essential medium (DMEM)
supplemented with 10% fetal bovine serum and antibiotics.
Murine brain endothelial cells were isolated from H-2Kb-
tsA58 mice (Charles Rivers Laboratories, Wilmington, MA)
as previously described [21]. Antibodies directed against the
phosphorylated forms of EGFR, MAP kinase, Akt, and Stat3
were purchased from Cell Signaling Technology (Beverly,
MA), and those recognizing the intracellular domain of EGFR
(sc-03) and CD3~ (sc-20919) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA).
Reagents
PKI166 (4-phenethylamino-6-[hydroxy]phenyl-7H-pyr-
rolo[2.3-d]-pyrimidine), an EGFR tyrosine kinase inhibitor,
was synthesized and provided by Novartis Pharma (Basel,
Switzerland) [23]. Human recombinant epidermal growth
factor was obtained from Invitrogen (Carlsbad, CA).
Expression Plasmids and Recombinant Lentiviruses
The full length of the human T-cell receptor signaling
complex CD3~ fragment, which was derived from a human
lymph node cDNA library (Edge Biosystems, Gaithersburg,
MD), was obtained by high-fidelity polymerase chain reaction
using Pfu DNA polymerase (Stratagene, La Jolla, CA). The
amplified fragment was constructed in the pLCMV6.1 lenti-
viral vector in which the human cytomegalovirus (CMV) pro-
moter drives the expression of theCD3f gene. pLCMV6.1 is a
modified version of the lentivirus vector pLL3.7 [24], and
a fragment containing the U6 promoter and enhanced green
fluorescence protein expression cassette in the pLL3.7 vector
was replaced by the CMV promoter and a multiple cloning
site. The CD3-EGFR chimeric receptor was constructed by
fusing the fragment containing an N-terminus of CD3~ (amino
acids 1–70) with the entire intracellular domain of human
EGFR derived from a pCHC/EGFR expression plasmid. The
fusion fragment of CD3-EGFR was then constructed in the
pLCMV6.1 vector.
Recombinant lentivirus was generated by transient trans-
fection of the lentiviral vector together with packaging plas-
mids consisting of expression plasmids for Gag-Pol, Rev,
and VSV-G (Invitrogen). Virus-containing supernatants were
collected 48 hours after transfection and introduced into
target cells according to the manufacturer’s instructions.
Transfection and Immunoblot Analysis
HEK cells were plated into individual wells of six-well
plates at a density 1  106 cells/well. After 24 hours of in-
cubation, the cells were transiently transfected with expres-
sionplasmids usingPolyFect reagent (Qiagen, Valencia,CA).
Twenty-four hours later, the cells were lysed with buffer
[20 mM Tris–HCl (pH 8.0), 137 mM NaCl, 10% glycerol,
2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 2 mM
sodium orthovanadate, 20 mM leupeptin, and 0.15 U/ml apro-
tinin], and 20 ml of total protein was resolved in 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis followed
by immunoblot analysis as previously described [25].
Cell Proliferation Assay, Soft Agar Assay,
and Fluorescence Imaging Analysis
Methods for assessing the in vitro proliferation of cells,
for examining the anchorage-independent growth of cells
in soft agar, and for visualizing the activation status of
intracellular signaling molecules were carried out as de-
scribed previously [25].
Cell Migration, Invasion, and Production of Matrix
Metalloproteinase (MMP) 9
To determine the migration of brain endothelial cells
expressing either CD3~ or CD3-EGFR in response to an
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angiogenic stimulus, we placed 10 ng/ml basic fibroblast
growth factor (bFGF; R&D Systems, Minneapolis, MN) in
500 ml of DMEM containing 2.5% fetal bovine serum into the
lower chambers of 24-well plates. Sterile 8-mm migration
inserts (BD Biosciences, Bedford, MA) were prewetted with
serum-free medium for 30 minutes, and then the medium was
aspirated. The inserts were placed onto 24-well plates; 4.0 
105 brain endothelial cells expressing CD3~ or CD3-EGFR
were resuspended in 1 ml of DMEM containing 2.5% fetal
bovine serum; and 100 ml of cell-containing suspension was
added to the upper compartment of individual inserts. The
assay was terminated after 6 hours, and the inserts were fixed
and processed for cell counting. The number of migrating cells
in four high-power (200) fields was recorded. Invasion as-
says were performed by coating 8-mm inserts with Matrigel
matrix (5 ng/filter; BD Biosciences) and placing them into wells
containing 500 ml of serum-free medium. Cells expressing
CD3~ or CD3-EGFR were resuspended in serum-free me-
dium at a density of 5.0  105 cells/ml, and 100 ml of this sus-
pension was added to the upper compartment. After 24 hours,
the inserts were processed, and the numbers of invading cells
were recorded as described above. Levels of collagenase
activity were determined as previously described [26].
Results
To generate a constitutively active EGFR, we created an
inherently dimerized chimeric receptor CD3-EGFR by ge-
netic reconstruction of wild-type EGFR (wtEGFR) (Figure 1A).
The cytoplasmic domain of wtEGFR was fused with the
extracellular and transmembrane domains derived from
CD3~ by exploiting a unique feature of the CD3~ chain
that allows it to form homodimers through its extracellular di-
sulfide bond [27]. This protein was targeted to the cell mem-
brane, where it spontaneously homodimerized due to inherent
dimerization (Figure 1B). To validate this dimerization, we
Figure 1. CD3-EGFR is a chimeric receptor containing a constitutively active EGFR tyrosine kinase. (A) Construction of the CD3-EGFR chimeric receptor. A
fragment containing the extracellular and transmembrane (EX/TM) domains of CD3f was fused with the cytoplasmic (CYTO) domain of EGFR. (B) Schematic
depiction of the CD3-EGFR chimeric receptor. The predicted structure of CD3-EGFR is that of a membrane-bound dimer resulting from inherent homodimerization
through the extracellular CD3f disulfide bond. (C) Evaluation of dimerized CD3-EGFR in transiently transfected HEK cells using immunoblot analysis. Lanes 1, 3, 5,
and 7 contain protein lysates from vector-transfected HEK cells, whereas lanes 2 and 4 show dimeric and monomeric CD3f proteins, respectively. The symbols ()
and (+) denote nonreducing and reducing electrophoretic conditions, respectively. Lanes 6 and 8 show the dimeric and monomeric forms of CD3-EGFR,
respectively, which were detected by an antibody directed against the intracellular domain of EGFR. (D) Examination of the tyrosine kinase activity of CD3-EGFR.
Cellular protein extracts from HEK cells transfected with vector (lane 1), CD3f (lane 2), or CD3-EGFR (lane 3) were analyzed with the indicated antibodies. Actin
was used as a loading control. (E) Activation of wtEGFR by EGF. wtEGFR was transfected into HEK cells, and the basal level of EGFR phosphorylation was
compared with that of cells stimulated with 40 ng/ml EGF for 15 min. (F) SB2 cells were stably transduced with lentivirus encoding CD3f (lanes 1 and 3) or CD3-
EGFR (lanes 2 and 4). The total protein extracts prepared from the cells 1 or 4 weeks after transduction were analyzed for phosphorylated CD3-EGFR (EGFR
Y1068) and total CD3-EGFR protein. (G) wtEGFR was cotransfected with CD3f (lanes 1 and 3) or CD3-EGFR (lanes 2 and 4) into HEK cells. Cells were harvested
for evaluation of phosphorylated wtEGFR and CD3-EGFR 24 h after transfection.
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transiently expressed CD3-EGFR in HEK cells, which are
deficient in EGFR. As shown in Figure 1C, the full length of
CD3~ was detected as a 16-kDa monomeric protein under
reducing electrophoretic conditions and as a 32-kDa dimeric
protein under nonreducing conditions. Likewise, the mono-
meric form of CD3-EGFR was observed as a 75-kDa protein
under reducing conditions and as a 150-kDa homodimer in
nonreducing conditions. Both the monomeric and dimeric
forms of CD3-EGFR were detected with an antibody recog-
nizing the intracellular domain of EGFR. Collectively, these
results demonstrate that theCD3-EGFRchimera expressed in
mammalian cells forms a homodimer independently of ligand.
To determine the activity of CD3-EGFR, we mapped
phosphorylation patterns of the chimeric receptor on distinct
cytoplasmic tyrosine residues in transiently transfected HEK
cells. In the absence of EGF, ectopic expression of CD3-
EGFR resulted in profound tyrosine phosphorylation of the
receptor predominantly at Y845 and Y1068 (Figure 1D).
Phosphorylation was also evident on Y1045, albeit to a lesser
extent. Y845 is the tyrosine residue phosphorylated by acti-
vated c-Src, and Y1068 is a prominent autophosphorylation
site. Both tyrosine sites are essential for activating down-
stream Stat3 in EGFR signaling [28]. The strong tyrosine
phosphorylation at these two residues indicated that the
expression of CD3-EGFR in cells induced the activation of
c-Src and Stat3. By comparison, transient transfection of
wtEGFR in HEK cells was associated with a low basal level
of tyrosine phosphorylation that was significantly enhanced
by stimulating the cells with EGF (Figure 1E ).
To determine the integrity of kinase activity in CD3-
EGFR–expressing cells, we stably transduced human mela-
noma SB2 cells (which are endogenously EGFR-deficient
cells) by using a recombinant lentivirus encoding CD3~ or
CD3-EGFR and monitored the resulting activity. The kinase
activity of CD3-EGFR was sustained for at least 4 weeks
without any notable decline (Figure 1F ). To test the possibility
that introduction of CD3-EGFR stimulates the activation
of wtEGFR, we cotransfected the chimera and wtEGFR
into HEK cells. In the absence of ligand, CD3-EGFR over-
expression induced only a slight increase in wtEGFR
phosphorylation; in the presence of EGF, wtEGFR phos-
phorylation was unchanged (Figure 1G). Collectively, these
data suggest that CD3-EGFR exhibits constitutive kinase ac-
tivity resulting from spontaneous generation of a homodimer
and that this activation duplicates wtEGFR activity in the
presence of ligand.
Next, we examined CD3-EGFR–expressing HEK cells to
determine the activation status of the downstream effectors
MAP kinase, Akt, and Stat3. As we have described, in the
absence of EGF, both MAP kinase and Stat3 were constitu-
tively activated in these cells. These activation patterns were
consistent with those of EGF-treated HEK cells previously
transfected with wtEGFR: in control HEK cells transduced
with CD3~ , the activity of Stat3 was at a basal level, and the
MAP kinase level was below detectable limits. These results
were supported by fluorescence imaging data, which dem-
onstrated that activated CD3-EGFR anchored to the cell
membrane (Figure 2, panel H ) and tyrosine-phosphorylated
Stat3 localized to the nuclear compartment (Figure 2, panel I ).
Akt was constitutively tyrosine-phosphorylated in parental
HEK cells (Figure 2, panel A), and expression of CD3-
EGFR enhanced Akt phosphorylation (Figure 2, panel G).
In general, small-molecule inhibitors of EGFRare designed
to repress the receptor kinase activity that results from bind-
ing of the ligand. To determine whether our CD3-EGFR
chimera was sensitive to such inhibition, we transfected HEK
cells with wtEGFR and then treated the transfected cells with
EGF alone or with PKI166. Stimulation of cells with EGF re-
sulted in a strong tyrosine phosphorylation of both wtEGFR
and Stat3 (Figure 3A, lane 2); these activities were completely
suppressed by 1 mM PKI166 (Figure 3A, lane 3). Next, we
introduced CD3-EGFR into HEK cells and noted that the
ligand-independent phosphorylation of the chimeric recep-
tor was also sensitive to treatment with PKI166 (Figure 3A,
lane 5 ). The ectopic expression of CD3-EGFR was at a basal
level higher than that of wtEGFR (Figure 3A, lanes 1 and 4),
Figure 2. Parental HEK cells and cells expressing CD3f or CD3-EGFR were plated onto four-chamber slides at a density of 2  104 cells per chamber in DMEM
containing 10% fetal bovine serum. After a 24-hour incubation period, the cells were fixed in acetone and stained with antibodies recognizing phosphorylated forms
of Akt (A,D, and G), EGFR (B,E, and H), and Stat3 (C,F and I).
1068 Construction of Constitutively Active Chimeric EGFR Cheng et al.
Neoplasia . Vol. 7, No. 12, 2005
presumably as a result of the enhancedstability ofCD3-EGFR.
Thus, an increased concentration of PKI166 (5 mM) was
required to completely quench the kinase activity of the
chimera (Figure 3A, lane 6). We thought it interesting that
CD3-EGFR still exhibited detectable activity in the presence
1 mM PKI166 even though the chimera-induced Stat3 tyrosine
phosphorylation had declined to the basal level (Figure 3A,
lane 5 ). These data suggest that Stat3 is exquisitely sensitive
tominor alterations in EGFRactivity. Furthermore, in SB2 cells
that stably expressed CD3-EGFR, persistent kinase activity of
the chimera was observed and, similar to HEK cells express-
ing CD3-EGFR, this activity was completely inhibited by 1 mM
PKI166 (Figure 3B). These experiments demonstrate that the
conformation of the kinase domain of CD3-EGFR approxi-
mates the conformation of ligand-activated wtEGFR and that
both are sensitive to inhibition by PKI166.
Ectopic expression of CD3-EGFR in murine brain endo-
thelial cells signals for angiogenic program activation
and continuous proliferation. Activation of EGFR in tumor-
associated blood vessels may be essential for the sustained
growth and metastasis of some tumors [17–20]. To deter-
mine the effect of CD3-EGFR on endothelial cell processes,
we stably expressed the CD3-EGFR transgene in murine
microvascular brain endothelial cells. To exclude any po-
tential confounding effects of SV40 large T protein expression
on our analyses, we cultured the cells at 37jC at least
72 hours before experimental analysis. At this time, SV40
large T antigen is no longer detectable in the cells (data not
shown). As observed in CD3-EGFR–expressing HEK cells,
we noted the phosphorylation of the receptor at Y845 and
Y1068 in CD3-EGFR–expressing brain endothelial cells
(Figure 4A). Introduction of CD3-EGFR, but not of CD3~,
stimulated the autophosphorylation and activation of Stat3
(Figure 4B). MAP kinase, however, was activated in both
CD3~- and CD3-EGFR–expressing cells. The persistent ac-
tivity of MAP kinase did not result from the introduction of
transgenes because parental brain endothelial cells also ex-
hibited spontaneous MAP kinase activity (data not shown).
Because activated EGFR has been identified in the vascu-
lature of tumors and not in the blood vessels of normal adja-
cent tissue [17,19], wequestionedwhether this tyrosine kinase
might be signaling for processes involved in angiogenesis.
Because endothelial cell proliferation is a prerequisite for
the growth of malignant tumors, we compared the rates of
cell division in brain endothelial cells that are genetically re-
constructed to express CD3~ or CD3-EGFR. Our examination
revealed that the cells expressing the chimeric EGFR grew at
a rate that was six-fold higher than that of CD3~-expressing
cells (Figure 4C). Next, we sought to determine whether
other endothelial cell processes necessary for the assembly
of new vascular structures were also affected by continuous
signaling through the EGFR. We found that the migration of
CD3-EGFR–expressing cells in response to bFGF was al-
most three times that of CD3~-expressing cells (Figure 4D).
Themigration of endothelial cells in response to an angiogenic
stimulus is known to be coupled to the synthesis of proteo-
lytic enzymes that target the parent vessel and modify the
surrounding extracellular matrix [29]. In this study, we found
Figure 3. The CD3-EGFR chimeric receptor is sensitive to the EGFR tyrosine kinase inhibitor PKI166. (A) The kinase activity of HEK cells expressing wtEGFR
(lanes 1–3) and CD3-EGFR (lanes 4–6) is inhibited by PKI166. The expression plasmid for wtEGFR or CD3-EGFR (1 g) was transfected into HEK cells. wtEGFR-
transfected cells were treated with EGF (40 ng/ml) alone or in combination with PKI166 (1 M) for 60 minutes. CD3-EGFR– transfected cells were treated with
1 M (+) or 5 M (++) PKI166 for 60 minutes. Total cellular protein extracts were prepared to analyze expression and phosphorylation at specified tyrosine residues
of wtEGFR and CD3-EGFR. Tyrosine-phosphorylated and total Stat3 protein levels are also shown. (B) Suppression of the constitutive activity of CD3-EGFR by
PKI166 in human melanoma SB2 cells. Parental SB2 cells (lanes 1 and 4) and SB2 cells stably transduced with either CD3f (lanes 2 and 5) or CD3-EGFR (lanes 3
and 6) were used. Untreated cells (lanes 1–3) or cells treated with 1 M PKI166 (lanes 4–6) for 60 minutes were prepared and analyzed for CD3-EGFR
phosphorylated at Y1068 and total CD3-EGFR. Actin was used as a loading control.
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that the brain endothelial cells expressing CD3-EGFR
released significantly more MMP-9 than did the CD3~-
expressing cells (Figure 4E ). In vivo, the regional destruction
of the surrounding microenvironment is accompanied by en-
dothelial cell invasion. We found that sustained EGFR signal-
ing in brain endothelial cells significantly increased their
invasive capacity (Figure 4F ). We also noted that the CD3-
EGFR–expressing cells were capable of continuous growth
on soft agar,whereas those expressing only CD3~ were not
(Figure 4G). Furthermore, the proangiogenic phenotype of
CD3-EGFR–expressing cells could be reverted by treating
them with 1 mM PKI166 (Figure 4H ). Collectively, these re-
sults suggested that persistent activation of EGFR on brain
endothelial cells signals for processes necessary for neo-
vascularization and leads to excessive proliferation. The latter
finding lends credibility to the hypothesis that sustained acti-
vation of EGFR on blood vessels supplying malignant tumors
may result in the generation of genetically unstable cells [30].
In fact, our phenotypic assessment of these cells is remarkably
similar to that from a recent report, which determined that
activated Stat3 is localized to tumor endothelial cells in human
gliomas and medulloblastomas [31].
Discussion
The primary motivation for the current study was to establish
a relevant cell-based system that could be used to identify
EGFR-activated intracellular effectors that may serve as
potential targets for therapy. To achieve this objective, we
first established a new methodology to generate a chimeric
constitutively active EGFR. We demonstrated that the con-
formation of the kinase domain of CD3-EGFR closely ap-
proximates that of ligand-activated wtEGFR and that both
forms are sensitive to the protein tyrosine kinase inhibitor
Figure 4. Ectopic expression of CD3-EGFR in murine brain endothelial cells induces Stat3 activation, angiogenic response, and anchorage-independent growth.
(A) The constitutive activity of CD3-EGFR expressed in cells. Cells were stably transduced with CD3f (lane 1) or CD3-EGFR (lane 2), and the cells were
maintained in culture for at least 4 weeks before analysis, when total protein extracts were prepared. Total CD3-EGFR protein, the form phosphorylated at Y845,
and the form phosphorylated at Y1068 are shown. (B) MAP kinase (ERK) and Stat3 expression in cells expressing CD3f (lane 1) or CD3-EGFR (lane 2). Protein
extracts prepared from stably transduced cells were analyzed for phosphorylated ERK, total ERK, phosphorylated Stat3, and total Stat3. (C) Enhanced proliferation
of cells that express CD3-EGFR. Cells were plated at a density of 2  105 cells in large dishes and counted at the indicated time points. (D) Enhanced migration of
CD3-EGFR–expressing cells to 20 ng/ml bFGF. The number of migrating cells was counted under 200 magnification 6 hours after the addition of cells. (E)
Enhanced production of MMP-9 by CD3-EGFR–expressing cells. (F) Cells expressing CD3-EGFR have enhanced invasiveness. This increased invasiveness
through 8-m inserts coated with Matrigel (5 ng/insert) correlated with increased MMP-9 production. The assay was conducted in serum-free medium and ended
24 hours after the plating of 5.0  104 cells. Cells were counted under 200 magnification. (G) Anchorage-independent growth of CD3-EGFR–expressing cells in
soft agar (0.3%). Cell growth was evaluated 2 weeks after plating. (H) Reversion of the anchorage-independent growth phenotype of CD3-EGFR–expressing cells
by 1 M PKI166.
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PKI166. We chose to introduce the chimera into brain endo-
thelial cells to pattern the phenotype of endothelial cells
found in malignant tissues. Previous studies have utilized
the EGFR mutant EGFRvIII to examine the effects of ligand-
independent EGFR activation [32,33]. Our decision to model
constitutive wtEGFR activation was based on those studies
describing differences between wtEGFR and EGFRvIII intra-
cellular signaling cascades [34] and sensitivity to receptor
tyrosine kinase inhibitors [35,36]. Moreover, we are unaware
of any reports documenting EGFRvIII expression in tumor-
associated endothelial cells; thus, introduction of the mutant
receptor into brain endothelial cells would not accurately
reproduce a key feature of tumor vasculature. Stable expres-
sion of CD3-EGFR in brain endothelial cells signaled for cell
division, migration to an angiogenic stimulus, elaboration of
proteolytic enzymes, and invasion—each of which is neces-
sary for the generation of a new blood vessel. By comparing
the phosphorylation patterns between the CD3~- and CD3-
EGFR–expressing brain endothelial cells, we determined
that the intracellular effector Stat3 is a central mediator that
regulates the response of these cells. Our findings (that sus-
tained activation of Stat3 is observed only in CD3-EGFR–
expressing cells and that PKI166 suppressed Stat3-induced
proliferation) support this determination.
STAT proteins are members of a family of transcription
factors that exist in a hypophosphorylated state in the cell
cytoplasm. Binding of various ligands (e.g., cytokines, hor-
mones, and growth factors) to their cell surface receptors
results in STAT activation and leads to the generation of
homodimers and heterodimers that enter the nucleus and
bind target gene promoters [37]. STAT proteins play a central
role in a number of biologic processes, including cell devel-
opment, differentiation, proliferation, and immunologic re-
sponses [38]. Recently, much attention has focused on the
contribution of aberrant STAT signaling to human disease
processes. In cancer, constitutive Stat3 activity appears to be
prevalent: it has been identified in malignancies originating
from the breast [39], lung [40], brain [41], head and neck [42],
and other human tissues. Many of these tumors appear de-
pendent on Stat3 signaling for their growth and survival;
consequently, Stat3 is rapidly emerging as an important
target for drug intervention [43]. However, considerably less
is known about the role of Stat3 signaling in vascular endo-
thelial cells. Our data suggest that targeting of Stat3 ac-
tivation, particularly in tumors expressing TGF-a, could
effectively halt neoplastic growth by affecting both tumor cells
and tumor vasculature.
The approach we used might be applied more broadly to
study receptor function in the context of disease processes.
Indeed, the generation of constitutively active receptors in
itself may be useful for performing high-throughput analyses
in a cell-free system. Because it functions in a specific
fashion, the chimeric receptor system avoids much of the
interference and bias that may arise from the activation of
secondary receptors induced by some ligands. As we have
demonstrated, the introduction of continuously active recep-
tors into relevant cells provides important information at the
molecular and functional levels. We anticipate that our novel
approach will be useful for advancing knowledge about
different disease processes and for identifying new targets
for intervention.
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